Consensus for FY24 EPS is $4.49. Raises 2024 revenue view to $540M-$560M from $520M-$542M, consensus $554.6M.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANIP Upcoming Earnings Report: What to Expect?
- ANI Pharmaceuticals Announces the FDA Approval and Launch of L-Glutamine Oral Powder
- ANI Pharmaceuticals announces FDA approval, launch of L-Glutamine oral powder
- ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP
- ANI Pharmaceuticals’ Naproxen Delayed-Release Tablets approved by FDA